Publications by authors named "Solly George"
Article Synopsis
- The study focuses on the safety and immune response of the MEDI0457 therapeutic DNA vaccine combined with the anti-PD-L1 antibody durvalumab in patients with HPV-associated cancers.
- Twenty-one patients with recurrent HPV-16/18 cancers were evaluated, showing a 21% overall response rate and a disease control rate of 37%.
- Despite some positive outcomes, the study was discontinued due to a low overall response rate among cervical cancer patients, though the treatment was generally well-tolerated.
We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias. Patients with acceptable performance status (0-2), adequate organ function, and no active infection, received ruxolitinib 25 mg orally twice a day for 4 weeks (1 cycle). Response was assessed after every 2 cycles of treatment, and patients who completed 2 cycles were allowed to continue treatment until disease progression.
View Article and Find Full Text PDF